A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
WASHINGTON — President Trump’s new drug pricing policy, to tie certain U.S. drug prices to those in other countries, will cost a small cadre of drug makers millions, if not billions.
About the Author Reprints
